克唑替尼治疗间变性淋巴瘤激酶阳性非小细胞肺癌的疗效及不良反应的影响因素  被引量:3

Efficacy of crizotinib in the treatment of anaplastic lymphoma kinase positive non-small cell lung cancer and the influence factors of adverse reactions

在线阅读下载全文

作  者:李亚平[1] 赵蓉[2] LI Yaping;ZHAO Rong(Department of Geriatrics,the First People’s Hospital of Yunnan Province, Kunming 650032, Yunnan, China;Department of Oncology, the First People’s Hospital of Yunnan Province, Kunming 650032, Yunnan, China)

机构地区:[1]云南省第一人民医院老年医学科,昆明6500320 [2]云南省第一人民医院肿瘤科,昆明6500320

出  处:《癌症进展》2019年第8期922-924,928,共4页Oncology Progress

摘  要:目的探讨克唑替尼治疗间变性淋巴瘤激酶(ALK)阳性非小细胞肺癌的临床疗效及不良反应的影响因素。方法收集71例ALK阳性非小细胞肺癌患者的临床资料,根据治疗方法的不同将患者分为观察组(n=35)和对照组(n=36),观察组患者接受克唑替尼治疗,对照组患者接受多西他赛化疗。比较治疗后两组患者的临床疗效、不良反应发生情况及生存情况。采用Cox比例风险模型分析克唑替尼治疗后影响患者发生不良反应的危险因素。结果治疗后,观察组患者的总有效率为62.86%,高于对照组的36.11%,差异有统计学意义(P<0.05)。观察组和对照组患者的不良反应总发生率分别为25.71%和33.33%,差异无统计学意义(P>0.05)。Cox比例风险模型分析显示,年龄≥40岁是影响ALK阳性非小细胞肺癌患者发生不良反应的独立危险因素(OR=3.214,P<0.05)。随访1年,观察组患者的生存率为74.29%,高于对照组的50.00%,差异有统计学意义(P<0.05)。结论克唑替尼治疗ALK阳性非小细胞肺癌的疗效显著,安全性较高,年龄≥40岁是影响患者发生不良反应的独立危险因素。Objective To investigate the clinical efficacy of crizotinib in the treatment of anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer and the influence factors affecting the adverse reactions. Method The clinical data of 71 patients with ALK positive non- small cell lung cancer were analyzed retrospectively. All patients were assigned into two groups according to their respective therapy, with 35 cases in the study group, and 36 cases in the control group;crizotinib was administered in study group, while the control group was treated with docetaxel chemotherapy. The clinical efficacy, occurrence of adverse reactions and survival after treatment in both groups were compared. The risk factors of adverse reactions after treatment with crizotinib were analyzed through Cox proportional hazards model. Result The overall response rate in study group after treatment was 62.86%, and it was significantly higher than that of the control group at 36.11%, the difference was of statistical significance (P<0.05). The incidence of adverse reactions in study group and control group was 25.71% and 33.33% respectively, and there was no statistical difference between the two groups (P>0.05). The Cox proportional hazards regression analysis showed that, age≥40 years was an independent risk factor for adverse reactions among ALK positive non-small cell lung cancer patients (OR=3.214, P<0.05). Subjects were followed up for 1 year, the survival rate in study group was 74.29%, which was significantly higher than that in control group at 50.00%, demonstrating statistically significant difference (P<0.05). Conclusion Crizotinib is effective and safe in the treatment of ALK positive non-small cell lung cancer, and age≥40 years is an independent risk factor for adverse reactions.

关 键 词:克唑替尼 间变性淋巴瘤激酶 非小细胞肺癌 危险因素 

分 类 号:R734.2[医药卫生—肿瘤]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象